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 Introduction 
 As Chapter 1 briefly outlined, Kenya has a strong and long-standing 
pharmaceutical industry. A 2015 Business Monitor report on pharma-
ceutical manufacturing in Kenya states that the country hosts the largest 
pharmaceutical industrial base in East Africa. The report also sees a bright 
future as a ‘potential base for export across East Africa’ (BMI Research, 
2015). This chapter locates the Kenyan pharmaceutical industry within 
the country’s historical context of industrial development and growth. 
 The features of the local production of medicines are shaped by the 
characteristics of the Kenyan economic and industrial systems, which 
in turn are the product of its economic history. To analyse this shaping, 
this chapter briefly presents and then applies an evolutionary economic 
understanding of industrial capabilities, focusing particularly on techno-
logical capabilities at the firm and industrial system level, their sources 
and evolution. This framework of industrial analysis is also used in a 
number of subsequent chapters in this book. It is particularly illumi-
nating for the analysis of the development of an industry, pharmaceu-
ticals, that is technologically demanding relative to the industrial and 
economic context in a low-income country such as Kenya. 
 Pharmaceutical manufacturers face constant competitive and regula-
tory pressure to upgrade their technological capabilities, and the evolu-
tionary framework of analysis emphasizes the extent to which this 
upgrading relies on both firm-level investment building on existing 
capabilities, and also on the benefits that accrue from its surrounding 
industrial base. Chapter 1 briefly noted that African countries’ broader 
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industrial base frequently stems in turn from an era of policy-led 
import-substituting industrialization. This chapter explores in more 
detail how the pharmaceutical industry has built on this basis in 
Kenya, and the scope that gives the industry for exploiting the oppor-
tunities opened up by the subsequent more liberalized and competi-
tive markets. It also outlines some of policy decisions that have shaped 
the industry’s development, and some of the challenges for firms and 
policy makers. 
 This chapter draws on a range of sources, including trade and manu-
facturing data, secondary published and grey literature sources and also 
interviews with manufacturers and distributors and other field data 
collected in 2012–14. 1 
 The evolution of Kenya’s pharmaceutical industry in the 
context of post-colonial industrialization 
 The profile of the pharmaceutical industry in Kenya is influenced by the 
country’s broader economic and industrial history. The post-independ-
ence industrial history of Kenya can be split into three periods according 
to the policy regimes adopted: the early years of import substitution 
industrialization (ISI), until the 1970s; the liberalization and gradual 
opening up of the economy in the 1980s and 1990s; and the new millen-
nium (Chege, Ngui and Kimiyu, 2014). 
 Pharmaceutical production was already taking place before the advent 
of independence in 1963, as Chapter 1 described. The early firms were 
mainly foreign direct investments (FDI). The newly independent country 
then continued to implement policies of ISI that had started during the 
colonial period. 
 Import-substituting industrialization is a set of economic and trade 
policies that aim to promote domestic industrialization in order to 
reduce the country’s dependence on manufacturing from abroad. The 
policies seek to promote the accumulation of skills, capital and knowl-
edge for the production of manufacturing goods by limiting imports of 
selected manufacturing goods through a variety of trade restrictions and 
subsidizing domestic manufacturing enterprises. In the Kenyan case, 
local producers were shielded from foreign competition in manufac-
tures in a variety of ways. High tariffs, even reaching 100% of the goods’ 
value, and quotas were imposed on imported manufactures, which were 
also charged higher rail fares, with the result that their prices were high 
for Kenyan consumers. Domestic manufacturing firms were also helped 
with financial subsidies, allocated land for production facilities, and 
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allowed to have import duties refunded on the inputs (raw materials and 
equipment) they had to import for production. 
 The Kenyan government also explicitly welcomed foreign-owned 
firms who set up production facilities in the country, as they contrib-
uted to the domestic industrial development. The large weight of FDI 
in Kenyan industry of the colonial period is also typical of the early 
years of independence, when it even reached half of industrial output 
(Maxon, 1992). Fearing a flight of FDI, a year after independence, in 
1964, the government passed the Foreign Investment Act, which gave 
reassurances to foreign firms in areas such as repatriation of profits and 
protection from nationalization. 
 This policy orientation towards manufacturing for the domestic 
market was reinforced in the 1970s by balance-of-payments crises and 
rising oil prices which led to scarcity of foreign exchange. Manufacturing 
of consumer goods for the local market expanded rapidly in the early 
1970s, and there was diversification into upstream supplier indus-
tries such as plastics. In this period, pharmaceutical manufacturing 
expanded, benefitting from the industrial protection, and also from 
an active government policy to promote investment and technolog-
ical upgrading. Laboratories & Allied was incorporated in 1970. The 
government established the Industrial and Commercial Development 
Corporation (ICDC) to promote the inclusion of local people in industry 
by providing development finance and technical assistance. ICDC helped 
to develop pharmaceutical production in this period through parastatal 
joint ventures. Dawa was established as a 1970s joint venture between 
the ICDC and the Yugoslav government. A firm producing infusions, 
Infusion Medicare, began in the mid-1970s as a joint venture between 
the ICDC and Hoechst E.A. (the latter the East African arm of a German 
pharmaceutical producer now part of Sanofi). 
 ISI policy in this period successfully created an industrial base in Kenya, 
especially in light consumer industries such as textile and foodstuffs, but 
also in others such as metal products. Between independence and 1980, 
industrial output quadrupled, the share of GDP in manufacturing grew 
from 10.1% to 13.3% and the number of industrial establishments more 
than doubled (Ogonda, 1992: 297–98). The increase in local manufac-
turing reduced the multinational companies’ (MNCs) share of industrial 
output, which however still accounted for 20% of industrial output in 
the early 1970s (Maxon, 1992: 385). 
 However, the protection from international competition encouraged 
local firms to focus on the protected local market and neglect exports. 
This created an anti-export bias that, together with external shocks such 
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as the oil crises and a deterioration of terms of trade, led to a shortage 
of foreign exchange. In 1980 Kenya had to take a loan with the World 
Bank, which imposed structural adjustment conditions. This marked 
the beginning of the phase of liberalization and structural adjustment 
policies in the mid-1980s and 1990s, as it happened across Sub-Saharan 
Africa, and the beginning of a shift to export promotion. In Kenya, 
export promotion included a number of measures to allow production 
for exports using duty-free inputs, but the implementation was slow and 
tentative, with little impact on export. 
 The gradual opening up of local markets created competition that 
had an adverse impact on local industrial activity. Shortage in foreign 
currency contributed to the decline of domestic industry as firms found 
it difficult to buy foreign inputs and equipment, with adverse effects 
on capacity utilization and therefore productivity. After an economic 
crisis at the beginning of the 1990s, liberalization and export promo-
tion accelerated with the creation of Export Promotion Zones (EPZs), 
participation in the Common Market for Eastern and Southern Africa 
(COMESA) and the East Africa Community (EAC), and the removal of 
price controls in 1994. Export promotion and international competi-
tion, however, had little impact on pharmaceuticals in that period. More 
important was a push in the 1990s to ‘buy local’, aiming, for example to 
ensure that basic medicines kits should be 50% local products (Wamae 
and Kariuki Kungu, 2014). Local pharmaceutical companies benefitted 
from this policy – an example of active use of health sector procurement 
as an industrial policy. Among the larger Kenyan manufacturers, Regal 
was established in the 1980s and Universal in the 1990s. Parastatal firms 
were privatized. 
 The third phase of industrial development, in the new millennium, 
saw an increase in exports especially in textiles through the United 
States’ African Growth and Opportunity Act (AGOA), which facilitated 
exports to the US and increased activity in EPZs. In spite of this new 
push to promote exports, the pressure of global competition from other 
low-income countries has meant that the share of manufacturing in 
total GDP has not changed significantly, and much of industrial activity 
is still carried out in the informal sector by micro enterprises, whose 
small size makes it difficult to find funds for investment, expansion and 
upgrading. During these years, most of the foreign MNCs also ceased 
to produce in Kenya as they reorganized their supply chains globally in 
the light of competition from China and India to find cheaper locations 
for production. It is possible that local producers may have benefitted 
from the flight of production from MNCs, being able to take their place 
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in some market segments and absorbing employees already trained by 
foreign MNCs. 
 The development of Kenya’s pharmaceutical industry suggests that ISI 
policies were important to build an initial industrial base. Previous anal-
yses of industrialization have argued the ISI policies followed by careful 
liberalization and export promotion might be useful to promote indus-
trialization (see, e.g., Athreye, 2004, for the Indian software industry). 
So it is possible that ISI policies enabled Kenya to start the accumula-
tion of basic technological know-how, perhaps through parastatal joint 
ventures, such as those formed by ICDC, in spite of their problems. The 
opening up of export markets, especially with the creation of COMESA 
and EAC and the policies that promoted exports such as the formation of 
EPZs, also enabled the strongest firms to adapt to international competi-
tion and offered opportunities for the expansion that is observed today, 
as the next section shows. 
 The Kenyan pharmaceutical industry and 
its market position 
 In historical studies of industrialization in Kenya, the pharmaceutical 
sector is rarely mentioned as it traditionally accounted for a very small 
share of industrial output. However, recently its status has been increas-
ingly recognized. For example, pharmaceuticals are mentioned as one 
of the eighteen strategic sectors in the National Industrialization Policy 
2011–15 (Ministry of Industrialization, 2010). Kenyan local manufac-
turers of medicines have shown great resilience during the years of 
economic difficulties and are now embarked on a process of growth 
and technological upgrading that, if successful, can establish them as a 
major player in the East African market for medicines. 
 Kenya’s pharmaceutical production grew continuously from 2007 to 
2013. As Figure 2.1 shows, in that period total production of tablets, 
capsules, liquid preparations for oral use and creams/ointments alone 
increased from US$34.1 million to US$154 million. The figure also 
shows that the composition of products has changed over these years, 
with creams and ointments becoming more popular, although virtually 
all product types have steadily increased with the possible exception of 
capsules. 
 Kenya has also seen strong growth in its pharmaceutical exports in the 
new millennium, especially since 2002. Exports started growing around 
1992–93 thanks to the ‘buy local’ push, which promoted the expan-
sion of local manufacturing. However, during the 1990s and early 2000s, 
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local production was affected by the adverse effects of liberalization 
policies described in the previous section, and exports remained stable. 
These years also saw a wave of divestments of production activities from 
foreign-owned companies that carried on in the new millennium as 
Kenya’s industrial environment deteriorated and MNC producers moved 
out of Kenya to lower cost platforms. By 2014, only one MNC was still 
manufacturing in Kenya – GSK. Otherwise, pharmaceutical firms in 
Kenya are currently mainly locally owned. 
 The great majority of Kenyan’s pharmaceutical exports are destined 
to Sub-Saharan Africa (SSA). COMESA is the main export destination 
for Kenya’s pharmaceutical exports, with Kenya supplying about 50 per 
cent of the region’s production. In relative terms, however, this trans-
lates into a minute share of the COMESA market. 
 With respect to the main importers of Kenya’s pharmaceutical prod-
ucts, Uganda has remained a significant market over a number of 
decades. Somalia and Sudan have also seen significant growth of Kenyan 
products, particularly over the last two decades. 
–
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 Figure 2.1  Local production of non-parenteral medicines in Kenya by type of 
product, 2007–13 (US$ million) 
 Source : Kenya National Bureau of Statistics, Production data for the period 2007 to 2013, 
Government of Kenya, Nairobi, obtained 4 September 2014. 2 
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 In spite of the growth in production and exports, the Kenyan phar-
maceutical industry has to overcome important challenges in order to 
consolidate and expand its influence in the East African region. Kenya’s 
pharmaceutical industry is still mainly oriented towards the home 
market, with an export share of domestic production only ranging 
between 15 and 20 per cent, at least up to 2010. Furthermore, the Kenyan 
producers’ share of their own home market is estimated at around 25% 
of domestic demand (see also Chapter 8), leaving room for expansion 
(Wamae and Kariuki Kungu, 2014). 
 Kenyan manufacturers sell to the Kenyan public procurement agency 
KEMSA, and to the large non-profit wholesaler the Mission for Essential 
Drugs Supply (MEDS) that supplies predominantly the faith-based health 
care sector. They also sell into the large private sector (Chapter 8). Public 
procurement is regulated by the Public Procurement and Disposal Act 
of 2005, and tendering decisions are based mainly on pricing, though a 
15% price preference for local manufacturers is available. Producers and 
distributors are free to set their own prices and mark-ups, and private 
mark-ups are, on average, high. The pricing of medicines in Kenya was 
completely liberalized in 1993. 
 In the new millennium the Kenyan domestic medicines market has 
been hit by more global competition, notably from South Asia. A key 
development for the pharmaceutical industry has been the large-scale 
movement of donors into supplying medicines for malaria, TB and 
especially HIV/AIDS. This has been a strong influence on the domestic 
market and pharmaceutical policies in a number of the countries 
discussed in this book. The arrival of the large donors was, however, 
somewhat later and more patchy in Kenya than in some neighbouring 
countries. PEPFAR, for example, the main US programme for funding 
HIV/AIDS medication, began to operate in Kenya only in 2008, and 
Kenya received no funding under Rounds 8 and 9 of the Global Fund 
financing (UNIDO, 2010: 41). 
 The production capabilities of the Kenyan industry were confirmed 
during this period by the companies’ role in the campaigning that led 
to the 2001 government decision to allow compulsory licensing of 
generic production of HIV/AIDS medicines, and the subsequent issuing 
of voluntary licences (UNIDO, 2010). However, private importers from 
South and East Asia were increasingly generating price-based competi-
tion in the Kenyan medicines market as liberalization took hold. With 
export figures that in absolute terms remain very modest, it is essential 
that Kenyan manufacturers keep upgrading and also control costs in 
order not only to expand its foreign markets but also to keep up with 
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increasingly demanding technological standards and cheap foreign 
competition that creates a serious challenge to local producers. 
 Technological capabilities and sectoral systems of 
innovation 
 The previous sections have shown that Kenyan pharmaceutical manu-
facturers are enjoying a period of growth. However they also face chal-
lenges that arise from cheap imports and the need to constantly upgrade 
their technology in order to keep up with global competition and 
increasingly demanding technical standards and to successfully exploit 
new market opportunities. A key factor in the future prospects of the 
Kenyan pharmaceutical industry is therefore the extent to which the 
local producers will be able to improve their technological capabilities. 
 The notion of technological capabilities, which has now entered the 
mainstream analysis of industrial development, can be traced back to the 
work of evolutionary economists such as Richard Nelson, Sydney Winter, 
Christopher Freeman and Giovanni Dosi (Dosi et al., 1988; Nelson and 
Winter, 1982). Evolutionary economics started as a critique of the domi-
nant theoretical framework in economics, the neoclassical approach. The 
critique arose from the observation that the tools of neoclassical analysis 
were not well suited to the study of technological and industrial change. 
Neoclassical economics focuses on the working of the price mechanism 
in the coordination of economic activity but makes strong and unreal-
istic assumptions about the nature of technological knowledge and the 
way firms (and, in general, other economic agents) operate. Technology 
is seen as information, which has public good features and is therefore 
easily transferred between firms. Technology transfer is simplistically 
seen as the transfer of free information. 
 Evolutionary economists, however, argue that much of technological 
knowledge is tacit and hence difficult to articulate, let alone transfer 
easily. The effective use of technology requires that any publicly available 
technical information be processed using know-how and skills that not 
only are costly to acquire but also differ across firms, industries and coun-
tries. Firms and other organizations, like people, acquire skills, or capa-
bilities, that become embedded in their procedures (also called routines) 
and people through a process of learning that is shaped by the history 
of the firm. Technological capabilities, therefore, are the organizational 
skills that enable firms to make effective use of technologies, including 
the ability to adapt them, improve them and even develop radically 
new products and processes. Because of their tacit nature, capabilities 
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are costly to acquire, are learned over time and change slowly over time. 
An important consequence of this view is that since firms’ histories and 
sources of learning differ, the capabilities that firms accumulate also 
differ. Indeed, industry studies have shown that firms within the same 
industry usually have many differences that are persistent over time: 
each firm is unique (Griliches and Mairesse, 1995). 
 The work on capabilities of early evolutionary economists originally 
focussed on advanced technologies and firms in industrialized coun-
tries. However, other scholars, such as Lall, extended this work into the 
context of developing countries. In an influential paper, Lall (1992) 
distinguished between firm-level and country-level capabilities. Firm 
capabilities include both investment and production capabilities and 
can be classified according to their degree of complexity, from basic, 
which involve experience-based tasks, to intermediate, which involve 
an element of search, to advanced, which are research-based and involve 
the creation of wholly new products and processes. Firm capabilities also 
include ‘linkage capabilities’, the way in which firms learn from and 
transfer knowledge to the external environment, that is, other organiza-
tions and institutions, including customers, suppliers, government agen-
cies and science and technology providers. Countries also have distinctive 
national capabilities, which are more than the sum of the capabilities 
of their firms and other organizations because they also include they 
way economic agents interact and the features of the economic environ-
ment, such as the policies, incentives and institutions. 
 The early work on technological capabilities has been further devel-
oped by many scholars and has now entered mainstream thought in 
the field of science, technology and innovation studies (STI). A useful 
development of this theorizing is the recognition that industrial sectors 
have a set of institutions and organizations that differ across sectors and 
influence the way technological capabilities are accumulated and firms 
compete. In order to understand an industry’s patterns of development 
and change, it is necessary to study the various agents that influence 
the accumulation of knowledge and the nature of competition in the 
industry and the way they interact. 
 The pharmaceutical sector is a typical example of the distinctiveness 
of sectoral institutions that shape technological learning and competi-
tion. Medicines are usually strictly regulated for their efficacy and safety 
by government agencies in a way that is unusual in other industries. 
The structure of demand is also distinctive because of the important role 
played by the state through the public procurement of essential medi-
cines for the health system and, especially in low-income countries, the 
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major role played by international donors in the purchase of key medi-
cines. On the supply side, universities also play an important role as 
providers of skilled labour and scientific knowledge. 
 Technological capabilities in manufacturing of 
medicines in Kenya 
 This section draws on various sources, including firm interview data, in 
order to give an assessment of the Kenyan technological capabilities in 
the local production of pharmaceuticals. The technological capabilities 
of the Kenyan domestic pharmaceutical sector are analysed by looking 
at various dimensions of the production system in which local manufac-
turers of pharmaceutical operate. 
 The analysis starts with the description of the local producers because 
the firms are at the centre of the industrial system. A good starting 
point for the assessment of the manufacturers’ capabilities is the anal-
ysis of the characteristics of their products in terms of quality and tech-
nological sophistication, the extent to which they achieve industry 
standards and their productivity. What firms can achieve, however, 
also depends on the capabilities of the system of suppliers, customers, 
regulations and institutions with which they interact, including the 
educational and financial systems, so these aspects will be included in 
the analysis. 
 Industrial structure 
 Local manufacturing of pharmaceuticals in Kenya is dominated by 
locally owned firms. In 2014 there were 39 local manufacturing firms 
with products registered with the Pharmaceuticals and Poisons Board 
(PPB), the agency that regulates the manufacture and trading of medi-
cines in Kenya. Of these, 34 produced medicines for human consump-
tion, whilst at least five firms produced animal health products. Of the 
34 firms, only one producer is a foreign-owned MNC, GSK East Africa, 
which has not followed the exodus of other MNCs. Although MNCs 
dominated the local production of pharmaceuticals in Kenya in the 
1990s, because of the unattractive economic conditions in Kenya in the 
1990s and changes in global supply chains, most of them have moved 
production facilities to lower cost locations and are only present in 
Kenya for activities such as marketing and clinical studies (Wamae and 
Kariuki Kungu, 2014). 
 However, government policy has provided other incentives for 
local production by removing import duties and taxes from inputs to 
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pharmaceutical products, such as APIs, excipients and packaging mate-
rials. The situation, however, changed in 2013 when the new VAT act 
reintroduced taxation for pharmaceutical inputs and only exempted 
finished products. This decision made locally produced medicines up to 
22% more expensive, and the industry put pressure on the government 
to reverse the decision. This happened in the 2014 Act, but there are still 
some unresolved issues that are worrying local manufacturers (Wamae 
et al., 2014). 
 Studies of the Kenyan supply medicines chain show that Kenya has 
high margins for distributions, which raise the final price of the medi-
cines to users in spite of fairly low manufacturing costs, in comparison 
to countries, such as Brazil, India, Indonesia, Kenya, Netherlands, Russia 
and South Africa. The study shows that the percentage of distribu-
tion costs is clearly highest in Kenya (see IMS Institute for Healthcare 
Informatics, 2014: 11). The high margins are a sign of the market power 
enjoyed by private distributors, who have a global reach and access to 
cheap imports, mainly from India. 
 Products and standards 
 Kenyan manufacturers are mainly engaging in activities that require 
basic to moderate technological capabilities, such as formulation activi-
ties, that is, converting manufactured bulk substances into final usable 
forms, and packaging rather than activities at the high end of the 
technological spectrum, such as R&D aimed at the discovery of new 
molecules and product development or the production of bulk pharma-
ceutical substances (APIs). The tablet is the most common dosage form; 
Kenyan firms also manufacture capsules, topical preparations (creams, 
gels, ointments or pastes), liquid preparations for oral use (including 
syrups), injectable infusions (small and large volume parenteral prepa-
rations) and ophthalmic formulations. Topical preparations have seen 
significant growth between 2007 and 2013 (Figure 2.1) (Wamae and 
Kariuki Kungu, 2014). 
 Formulations, however, can vary substantially in terms of the techno-
logical capabilities required for production. Products such as injectable 
infusions and ophthalmic formulations require sterilization, which is 
achieved through a production process that is technologically complex 
and demanding in terms of meeting standards of safety, efficacy and 
quality – particularly for injectable infusions. There are three local firms 
that manufacture injectable infusions and a few others that produce 
sterile ophthalmic products, including Laboratories & Allied (Wamae 
and Kariuki Kungu, 2014). 
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 There are also important differences in the technological require-
ments within the group of non-sterile formulations. Some of the more 
technologically progressive firms have dedicated laboratories that 
undertake extensive product development activities with regard to 
existing products and are developing the capabilities for the produc-
tion of more technologically sophisticated products. For example, some 
firms are moving from plain tablets to modified-release and sustained-
release tablets. Some firms also engage in active process improve-
ments. Some producers already meet WHO-GMP standards, and are 
also upgrading their production processes to gain WHO recognition, 
which could possibly open the door to funding by international donor 
agencies. One company, Universal Corporation, has already received 
WHO prequalification for its Lamivudine/Zidovudine anti-retroviral 
product in 2011, and other firms, such as Cosmos, are aiming to gain 
pre-qualification in the near future. Other firms are attempting to gain 
GMP standards with the help of PPB and international agencies such as 
UNIDO (UNIDO, 2014). 
 Formal R&D activity (the discovery and product development of new 
active pharmaceutical ingredients) is in its infancy, with only one firm 
engaging in R&D. Another firm, Botanical Extract EPZ (or BEEPZ), is 
the only Kenyan firm developing capabilities for the production of 
artemisinin, which is used in the production of anti-malarials. BEEPZ is 
the development of an industrial concern born in 1996 in Tanzania to 
develop the production of high-quality  artemisia  annua with improved 
yields and artemisinin content. The project expanded its facilities to 
produce the raw materials in Kenya and Uganda, and in 2007 BEEPZ 
commissioned its principal processing facility in the export processing 
zone (EPZ) in Athi River, Kenya, currently producing non-API-grade 
artemisinin for export (Botanical Extracts EPZ, 2015). The expansion of 
production of  artemisia  annua to Kenya and Uganda was possible thanks 
to grants from the UK Department for International Development 
(DFID) and the multinational company Novartis, a leading producer 
of artemisinin-based anti-malarial drugs, which also became a BEEPZ 
customer in 2009, when the EPZ plant started production (IRIN News 
Africa, 2015). 
 There are also three local firms that process some raw materials that 
are used to manufacture bulk pharmaceutical products. These raw mate-
rials are 100% destined for export, as the local capacity for manufac-
turing active pharmaceutical ingredients remains underdeveloped. 
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 Productivity, capacity utilization and cost efficiency 
 Unfortunately, it is too difficult to obtain a direct measure of produc-
tivity for the various manufacturers, but it is well known that capacity 
utilization is an important determinant of productivity. Firms that only 
operate at a low level of capacity utilization are less efficient and can 
only achieve relatively low levels of productivity. 
 Annual capacity utilization for the manufacture of most dosage forms 
averages around 60%. Only injectable infusions experience higher 
capacity utilization ranging between 85 and 100%. A number of reasons 
have been identified from interview data. These include: the functioning 
state of machinery and equipment; delays in sourcing spare parts from 
abroad and specialized maintenance support from machinery and 
equipment suppliers; human resource issues and in particular highly 
specialized skills in some critical areas such as product development; 
perceptions of locally manufactured products by some market segments; 
and lack of policy coherence (Wamae and Kariuki Kungu, 2014). Some of 
these challenges have a direct impact on the competitiveness of locally 
manufactured products. 
 The interesting observation is that these factors seem to apply mainly 
to the supply side of the industry. In other words, limited capacity utili-
zation does not seem to be due to lack of demand. The previous sections 
showed that local producers only supply a quarter of the domestic 
market and a very small fraction, less that 1%, of the COMESA medi-
cines market, so there are plenty of opportunities for expansion. Indeed, 
Kenyan local manufacturers have the twofold challenge of having to 
increase capacity utilization and very importantly considering options 
for expanding their total capacity. 
 On the other hand, once the segments in which local producers 
operate, which are mainly fairly unsophisticated formulations of 
essential medicines, are taken into account, it is possible to see that 
Kenyan manufacturers operate in a very competitive sub-section of 
the market with many competitors, both domestic and importers, and 
where prices and therefore profit margins are low because of the low 
purchasing power of the consumers and the inability to access funding 
from donors because of lack of WHO prequalification (UNIDO, 2012). 
So the technological limitations of the manufacturers also contribute to 
relegating most of them to a narrow and highly competitive segment 
of the industry where demand for each firm’s product might well be 
constrained in some cases. 
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 Human resources and the educational system 
 Successful industrial production requires a range of different skills. 
Local universities, such as Jomo Kenyatta University of Agriculture and 
Technology, Mount Kenya University and the University of Nairobi, 
provide graduates with good-quality basic skills and training in phar-
macy, engineering and chemistry. Top polytechnics such as the Kenya 
Medical Training College are good sources for mid-level training. 
Employees also use foreign universities, for example in the UK, Germany 
and India. All firms also have compulsory training in-house. However, 
the internal education system cannot meet all industry requirements, 
especially as upgrading is needed. 
 Official reviews (UNIDO, 2012) and interviews suggest that there 
is a scarcity of pharmacists specialized in industrial pharmacy. The 
educational system has a high literacy rate and provides people 
well qualified in clinical pharmacy, but newly qualified employees 
need extensive training in the industrial aspects of drug production, 
including specialized training in industrial quality assurance. A key 
issue is that the teachers were originally trained in clinical pharmacy, 
so there is not a long tradition of industrial pharmacy in Kenya. 
University graduates have a good training in basic skills and theory, 
but many firms make use of training programmes run both internally 
and externally by international organizations, such as GIZ, Action 
Medeor and UNIDO. The latter sponsors popular courses such as the 
industrial pharmacy advanced training course run in Tanzania at the 
Kilimanjaro School of Pharmacy with the support of US universities 
(UNIDO, 2015). 
 Firms use some local training institutions, both public, such as the 
Kenya Medical Research Institute (KEMRI) and the PPB, and private. 
For advanced skills, however, they need to bring in experts from 
abroad, usually from India but also from other countries. Expatriates 
are expensive but important for quality because they have rare skills 
and experience in industrial processes. Usually they are offered short-
term contracts (two to three years), possibly renewed once but usually 
not longer because of permit limitations and because new people tend 
to have more up-to-date skills. Foreign experts are identified through 
various channels, such as suppliers, agencies, the Web, competitors and 
international agencies. 
 Finally, in some cases firms also use their informal networks to send 
employees to be trained abroad, with India being a popular destination 
because of the strength of the Indian pharmaceutical industry. So local 
manufacturers seem to be able to rely on solid internal supply of skills, 
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although at a fairly basic level, and to access expertise at a global scale 
even though the latter is subject to intense scrutiny because of its high 
costs. 
 Equipment and inputs 
 The shallow level of the Kenyan industrial sector is an important factor 
when inputs to production and equipment are considered. Kenya’s 
industry is one of the most developed in East Africa, and local producers 
can find local suppliers for basic inputs including packaging, with the 
exception of some more advanced packaging for sterile products, which 
is procured abroad, for example from China. Some more technologi-
cally complex packaging, such as over-pouches for injectables, used to 
be imported but are now produced locally. 
 Raw materials for production are mainly imported, due to the lack 
of producers of APIs and excipients. This dependence on imports is an 
important issue because it generates possible shortages which might 
influence production capacity, and additional costs even though phar-
maceutical inputs are supposed to be exempted from duties. In addition, 
Kenyan firms compete with imports produced by vertically integrated 
companies who also produce APIs, and are likely to price this key ingre-
dient above the competitive level. 
 Kenya does not have a developed industrial machinery sector, so the 
main machinery is imported from international suppliers. A popular 
source of equipment for pharmaceutical production is India followed 
by China, although language can be a barrier. India’s machines have 
the advantage of being significantly cheaper than those from industri-
alized countries and basically do the work well enough for tasks that 
do not require a high level of technological sophistication. Europe 
(especially Germany and Italy) and other high-income countries are 
the sources of more advanced and reliable machinery. The choice of 
suppliers is sometimes dictated by financial considerations: higher-
quality machinery might be not only more efficient but also more 
profitable in the long run. Companies, however, lack the resources 
for a high upfront investment in European machinery, in spite of the 
fact that the financial sector in Kenya is the most developed in East 
Africa. 
 The dependence on imports of machinery creates additional costs for 
local firms. Spare parts attract additional costs because imported prod-
ucts need to be checked and to obtain a quality stamp according to rules 
of the Kenyan Bureau of Standards. Additional inefficiencies are also 
created by the lags that occur in decisions during the process of import. 
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 Machines are operated by local engineers, who also keep records for 
GMP inspections, and are usually installed by suppliers who offer a 
comprehensive package of support including training and maintenance, 
at least for the first few years of life of the machines. 
 Some companies are currently looking to automate their production 
processes. Reduction of labour costs is one of the reasons, but improve-
ment of quality and productivity and reduction of human error and 
exposure in handling are more important factors. 
 Knowledge flows, linkage capabilities and innovation 
 As explained above, capabilities at the industry level depend not only on 
the capabilities of the various economic agents, such as manufacturers, 
but also on how effectively the various components of the industrial 
system interact and promote flows of knowledge. This section, there-
fore, looks in more detail at the flows of knowledge in the system and 
how these influence the accumulation of capabilities within firms. 
 Medicine producers develop their capabilities by acquiring knowledge 
from the external environment and through experience accumulated 
through a process of learning-by-doing over time. An important input 
to the firms’ capabilities comes from the education and training activi-
ties of its workers, as discussed above. Firms, however, can step up their 
accumulation of knowledge by explicitly investing in learning. This can 
happen internally through formal or informal research activities and by 
acquiring knowledge from other firms – suppliers, customers and even 
competitors – or research institutions. Most of the firms interviewed 
mentioned the importance of suppliers as sources of useful knowl-
edge. Suppliers regularly train manufacturers’ employees to use their 
machinery. Furthermore, by coming into contact with many different 
firms, suppliers gain useful knowledge about the industry and can be 
used as sources of technological knowledge or to identify people and 
firms with specific expertise that is useful for a company. Since Kenyan 
firms use foreign suppliers, they have been able to tap into their 
suppliers’ knowledge networks in order to identify foreign experts to 
hire, good training programmes and foreign firms where they can send 
their employees to learn more about advanced industrial technologies: 
some firms, for example, have mentioned examples of employees sent 
to be trained in Indian firms. 
 As mentioned above, firms also gain valuable knowledge by hiring 
international experts from countries such as India, South Africa and 
even European countries. Hiring expatriates and sending employees 
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to train abroad are expensive investments, so firms have schemes 
in which the trained employees relay the knowledge learnt to their 
colleagues. 
 As the innovation literature has pointed out since the work of Von 
Hippel, firms also learn from the users of their products (Von Hippel, 
1982). Some producers have stressed the importance of the feedback 
collected by their marketing teams. A firm selling sterile injectable prod-
ucts stated that important knowledge was learned from nurses who used 
their products, and changes were implemented following the nurses’ 
feedback. 
 Other common channels through which firms learn useful knowl-
edge are exhibitions (also abroad), websites, membership of profes-
sional associations and conferences. Manufacturers also learn from 
each other because employees move between firms or meet and have 
informal exchanges at training events and seminars. Flows of knowledge 
also occur through the industry associations, the Federation of Kenyan 
Pharmaceutical Manufacturers (KFPM) and the Federation of East African 
Pharmaceutical Manufacturers (EAFPM), which organize training events 
and other initiatives. 
 Regulatory agencies also provide firms with valuable knowledge. For 
example, PPB does not only carry out inspections but also helps manu-
facturers with advice, especially on issues relating to the acquisition of 
the GMP standard, including documentation relating to the audits, and 
on Good Laboratory Practice and Good Distribution Practice. Similarly, 
the National Quality Control Laboratory (NQCL) offers training and 
knowledge transfer in the areas of drug testing and medical instrumen-
tation, and Kenya Medical Research Institute (KEMRI) collaborates in 
the areas of research and training (KEMRI, 2015). 
 Licensing and joint ventures: the role of government policy 
 As the previous section has explained, the accumulation of technological 
capabilities occurs over time, and the current capabilities are influenced 
by past events. Because of the cumulative nature of technological knowl-
edge, policy initiatives can have a long-lasting impact on the capabilities 
of firms and industries. In the Kenyan case, there are two examples of 
policy intervention that can be said to have helped the development of 
technological capabilities in the industry: the provisions for compul-
sory licensing in the Trade-Related Aspects of Intellectual Property 
Rights (TRIPS) negotiations, and the policy of forming parastatal joint 
ventures with foreign MNCs in order to develop local capabilities based 
on foreign technology. 
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 In the case of licensing of foreign technology, Kenya campaigned 
vigorously during the trade negotiations that led to the TRIPS agree-
ment in order to be able to carry out compulsory licensing for some 
essential medicines. Compulsory licensing means that governments 
can issue licenses to manufacture medicines that are still protected by 
patents at more affordable prices than those set by foreign pharmaceu-
tical companies that hold the patents, without receiving the latter’s 
consent. Although in practice there has been no compulsory licensing 
in Kenya, it can be argued that the threat of compulsory licensing has 
enabled local firms to reach good licensing agreements with foreign 
MNCs. According to Garwood (2007), ‘Kenya has never issued a compul-
sory license, but came close to in 2004 before the German pharma-
ceutical major Boehringer Ingelheim agreed to enter into a voluntary 
license agreement with Kenyan drug firm Cosmos to produce generic 
versions of its patented anti-AIDS drug nevirapine’. Cosmos went on 
to enter another technology transfer agreement with Roche and is now 
one of the most dynamic Kenyan manufacturers, also aiming to gain 
WHO prequalification for the production of ARVs. The ‘buy local’ drive 
or procurement approach of the 1990s was also significant. It helped to 
lay a strong basis for the mushrooming of private local manufacturers: 
thus Cosmos would probably not have had its advantageous licensing 
position were it not for the ‘buy local’ move that was in effect very much 
steeped in ISI thinking. 
 As the above historical background pointed out, during the import 
substitution period, the government established ICDC to promote 
the development of local capabilities partly through parastatal joint 
ventures with foreign organizations. Joint ventures formed through the 
1970s with the Yugoslav government and a German firm are now the 
precursors of two dynamic Kenyan private firms: Dawa and Infusion 
Medicare, one of the producers of injectables. Cosmos was also origi-
nally formed as a joint venture. Now all three firms are wholly locally 
owned private firms, and critics of import substitution and ICDC inter-
pret the fact that the joint ventures had to be privatized as a failure 
of import substitution and ICDC (see, for instance, Himbara, 1993). 
However, it can be argued that although the parastatal status might 
have hindered the business development of the joint ventures, ICDC 
can still be said to be responsible for the creation of organizations that 
developed local technological capabilities that were later further devel-
oped by private capital. Possibly, without the initial policy of forming 
joint venture, companies like Dawa, Infusion Medicare and Cosmos 
would not exist today. 
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 The ISI policy involving joint ventures, of course, is not the only way 
to build industrial capabilities. In more recent years, Kenyan firms have 
found other ways to draw successfully on foreign capabilities. Two other 
producers of sterile products followed different strategies: one, facilitated 
by the assurance of a large government procurement, bought a South 
African firm outright and transferred the facilities to Kenya, whilst the 
other, which pursued an export-oriented strategy and is located in an 
EPZ, assembled a variety of suppliers and contractors to build a new 
plant with equipment sourced from various countries and drawing on 
international expertise. 
 Conclusions 
 This chapter has provided an outline of the local production of medi-
cines in Kenya, which is the leading manufacturer of pharmaceuticals in 
East Africa, accounting for half of the local production in COMESA and 
boosting rising production and exports. The Kenyan pharmaceutical 
industry is still small in relation to imports into Kenya and the whole 
of COMESA. However it constitutes a story of successful development of 
technological capabilities with examples of firms that are upgrading their 
technology and might be able to become leading players in East Africa, 
such as Universal, which has achieved enough technological capabilities 
to be awarded WHO prequalification. Kenya’s dynamic private sector 
and its access to COMESA and EAC are important strengths that suggest 
good prospects for Kenyan local producers. 
 However, obstacles and limitations remain, and the analysis in this 
chapter has shown that Kenyan firms have to upgrade successfully in 
order to compete effectively against strong imports. Kenyan pharmaceu-
tical producers have not yet been able to access donor funding, with only 
one firm achieving WHO prequalification so far. Most of the firms also 
operate in a highly competitive segment of the industry, the production 
of formulations of essential medicines, which offers low returns and pits 
them against very efficient imports. There are, however, success stories 
of firms that have reached significant technological sophistication, as 
in the case of the producers of injectables, and the analysis paints the 
picture of an industry integrating in global value chains, with access to 
global networks of equipment suppliers, foreign experts and training 
centres. 
 Still, there is work to be done to improve the regulatory environment, 
such as making sure that the VAT regulations do not disadvantage local 
firms, reducing the dependence of local manufacturers on imported raw 
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materials and promoting upgrading throughout the technologically 
weaker firms; the current strategy is to progressively move all firms from 
local to international GMP standards. 
 It is not straightforward to draw general lessons for the promotion of 
local production of pharmaceuticals in low-income countries given the 
messy economic history and diverse patterns of technological accumu-
lation this chapter has presented. It is possible, however, to suggest some 
possible tentative reasons that might have contributed to the observed 
successes of Kenyan pharmaceutical production. The chapter has argued 
that ISI policies, including the use of joint ventures at an early stage of 
industrialization, followed by gradual liberalization, might have been a 
positive factor in the accumulation of technological capabilities. Kenyan 
producers seem also to access global networks that are useful to iden-
tify and tap into rare skills and identify good equipment suppliers. The 
openness of Kenyan manufacturers may also be assisted by India-linked 
networks of some manufacturers with accumulated family experience in 
capitalist production from older merchant enterprises (Himbara, 1993). 
 On the whole, this chapter suggests a positive future for broadening 
and deepening pharmaceuticals production in Kenya. Despite an inter-
national and national context that is often less than helpful, consid-
erable progress has been made in the past few years and capabilities 
have been established that, while often unseen, are laying the basis for 
further growth. With a little extra help at the government level, Kenya 
might soon be a leading African nation in the field. 
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